Ankasa Regenerative Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1K
- Market Cap
- -
Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
Phase 1
- Conditions
- Degenerative Spondylolisthesis
- Interventions
- Biological: ART352-L
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Ankasa Regenerative Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04378543
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States
🇺🇸Keck School of Medicine, University of Southern California, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath